 Extends Cash Runway into Q3 2021The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase Ia Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious DoseSEATTLE, WA ACCESSWIRE August 6, 2020 Aptevo Therapeutics Inc. 